QR code

Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations

Abstract Background The efficacy of definite for non‐small‐cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations has been preliminarily demonstrated. However, there is a paucity of data with which to compare the efficacy and safety of second‐ and third‐generation T...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Yue Hao, Manyi Xu, Jianan Jin, Jinfei Si, Chunwei Xu, Zhengbo Song
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Wiley 2023-08-01
Reeks:Cancer Medicine
Onderwerpen:
afatinib
efficacy
NSCLC
osimertinib
safety
uncommon EGFR mutation
Online toegang:https://doi.org/10.1002/cam4.6229
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items